Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept for DSA reduction in kidney transplant
NCT02078193Phase 4Completed
- Sponsor
- East Carolina University
- Start
- Nov 2013
- Primary completion
- Jul 2016
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of belatacept in kidney transplant rejection, sponsored by East Carolina University. Primary endpoint: Change of Donor Specific Antibodies (DSA) at 1 year. Started Nov 2013; status: completed.
02
Drugs
belatacept
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT02078193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02078193.